22.75

3.64% 0.80

After Hours: 22.75

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $22.75, with a volume of 239.75K. It is up +3.64% in the last 24 hours and down -2.32% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Previous Close:

$21.95

Open:

$22.34

24h Volume:

239.75K

Relative Volume:

0.48

Market Cap:

$1.01B

Revenue:

Net Income/Loss:

$-166.31M

P/E Ratio:

-5.1007

EPS:

-4.4602

Net Cash Flow:

$-160.59M

1W Performance:

-0.26%

1M Performance:

-2.32%

6M Performance:

+32.50%

1Y Performance:

+19.80%

1-Day Range:

$22.34

$22.98

1-Week Range:

$21.09

$23.20

52-Week Range:

$15.47

$27.22

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

2026-03-04

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	22.75	970.23M	0	-166.31M	-160.59M	-4.4602
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Dec-10-25	Initiated	BTIG Research	Buy
Nov-25-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

02:00 AM

Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - Defense World

02:00 AM

ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - MyChesCo

02:00 AM

Mar 24, 2026

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha

Mar 24, 2026

Mar 23, 2026

Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily

Mar 23, 2026

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat

Mar 23, 2026

B. Riley Securities Maintains Buy on ArriVent... - Benzinga

Mar 23, 2026

Mar 21, 2026

Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn

Mar 21, 2026

Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm

Mar 21, 2026

Mar 19, 2026

Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN

Mar 19, 2026

ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Mar 19, 2026

Mar 18, 2026

ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart

Mar 18, 2026

Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN

Mar 18, 2026

Mar 17, 2026

Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - The National Law Review

Mar 17, 2026

ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks

Mar 17, 2026

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times

Mar 17, 2026

ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView

Mar 17, 2026

ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026 - Stock Titan

Mar 17, 2026

Lung and ovarian cancer drug data from ArriVent to debut at 2026 AACR - Stock Titan

Mar 17, 2026

Mar 16, 2026

Stock Report: What drives Assurant Incs stock price2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn

Mar 16, 2026